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from GP!!b/llla to GPIIb/IIIa. from ,~/b to ,,,/~ and from -~P3 to GPltb/llla. 
¢elle¢fing th~ c0mpa~ affinity of ~x imab for both integrins. 
Conc/us/on: Abciximab can redistnbute between GPlth/llla and , ,~  re- 
ceplora/n vitro, suggesting that abctximab may have proPmged effects on 
~/~ on vascular cells in addition to sustained inhibition of PLT GPIIb/llla. 
• ~t ing  With Abcixlmab (ReoPro'") Oeci¢ases 
Target Lesion Revasculari~lion 
S.K+ Shatma, A. Kini, G Oangas, R. Vk~hun, Y. Rajawat, S. Ouvvun, 
J 0. Marmur, J.A. Ambrose. Mount Sinai Hospital, New York. USA 
Abciximab (Reopre") has been shown to decrease acute ischemic com- 
pl,:atK~ns and reduce clinical resteno3is following balloon angioplasty and 
coronan/atherectomy. Whether ReoPro offers similar benefit after stenting 
has not been evaluated. We analyzed the 30-day incidence ot malor adverse 
cardiac events (MACE) and the need for target lesion revasculanzation (TLR) 
in 388 consecutive slant patients: 78 with ReoPro and 310 without ReoPro. 
Patients with hail-out slanting were excluded. 
Results: As expected, ReoFro was used more frequently in MI and rest 
angina cases ('acute syndromes') and in the setting of multiple slants and 
muttivesset intervention. The incidence ot 30-da, y ~'~CE did not differ with 
ReoPro. However, the 9-month TLR was sigmticantly lower m the group 
treated with stent plus Reopro compared to stent alone: 
$1ent + ReoPro n = 78 $1ent alone n = 310 p 
Acute syndromes 68% 43"=0 001 
Multlvess~l s entlr~j 20% 10% 0 03 
Multiple stents :29°0 21°o 0 01 
Procedural success 98 7°0 98 3% NS 
30-d~y MACE 1 2=° 22% NS 
Vasculal complications 38% I 6=0 NS 
TLR 19% 30% 0.02 
MACE = acule/subacute stont hrombosis, Q- ML CABG or dealh 
Conclusion: The use of RecPro during stenting decreases long-term TLR 
compared to stenting alone. These results were evident even though the 
ReoPro treated group was at higher risk. ReoPre did not affect significantly 
the already low short-term MACE after stenting. Based on these preliminary 
results, the effect of ReoPro on angiographic in-stent restenosis warrants 
prospective investigation. 
I 1088-100 Act ivat ion  of  Platelets in P latelet-r ich Plasma by  
RotablaUon Is Speed Dependent  and Can Be 
Inhib i ted by Abc ix imab (c7E3 lab; ReoPro") 
M.S. Williams, B.S. Coller, H.J. V~n~nen. L.E. Scudder, J.D. Marmur. 
Mount Sinai Hospital New ~brk, New York, USA 
Background: Rotational atherectomy may be complicated by the =no*rcllow" 
phenomenon. Because platelet activation may contribute to this complication. 
we developed an in vitro system to test the effect of rotablation on platelets 
in the absence or presence of GPilb/illa blockade with abciximab. 
Methods: Platelet-nch plasma (PRP) was prepared from 22 healthy hu- 
man volunteers. PRP was divided into four samples: no treatment, 6D1 
(anti-GPIb), abciximab (anti- GPIIb/llla + £xvB3), and abciximab + 6D1. Sam- 
pies were pumped through a flow chamber containing a 2.5 mm burr rotating 
at various speeds, and then placed in an aggregometer and stirred at 3~C. 
Results: PRP samples tested in the absence of antibody underwent more 
rapid and extensive aggregation when rotablated at 150 and 180k rpm as 
compared to 0 rpm (p .- 0.00001 at both speeds). Preincubation of platelets 
with c7E3 Fab decreased the slope of aggregation at each retaliation speed 
(p = 0,09 for 70k and p .- 0,0001 for both 150 and 1801(rpm). The msuffs 
are plotted as mean slope of aggrngafion • $0 vs, rot~blatlon spe~:l Both 
light and electron microscopy revealed rotablat~n~nduced platelet damage 
at 150 and 180k rpm 
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Cor~clt/$1." Rolablalion causes speed-depeedenl plaleiel activation in 
PRP which can be ~igniflcantly reduced by pro.treating PRP with abcil. 
~mab These data s~ggest thai prelreatment of patients w~th abciximab may 
decrease rotablation-induced platelet aggregation dunng mtat~l  atherec- 
ferny, 
I 1088-10111 AbCillll~b Reduces the Need for Blilbout 
Stenting During I~rimary Angiopluty, The 
RAPPORT Tdal 
LA. Barr, S.J. Braner, A.A. Jones, OJ. Mofitemo, M.B Effron, EJ. Topoi. 
For the RAPPORT Investigators. Midwest Hearl Reseanch, Lombard. 
Illin~s. USA 
Background: Primary angmplasty for acute myocardial infarction (MI) is often 
complmafed by transient or permanent abrupt vessel Closure due to dis- 
sections, rec~l, or thrombosis, whch frequently leads to bail,out 511~'1tii~. 
AbcIximab, administered before angioplasty, has been shown to reduce the 
risk of acute vessel closure, but has not been tested dunng primary PTCA. 
Methods: Patents (ptsl with acute MI <12 hr. were randomly allocated 
to placebo (P) or abciximab (A - 0.25 mcg,~g bolus and 12-hour mfusmn 
at 0.125 mcoJkg/min} as an adjunct to pnmery balloon angmplasty. Slanting 
was allowed for large dissections or acute/threatened vessel closure ('TIMI 
flow <2). 
Results: The need for stenting in the three groups (intention-to,treat -fl-r 
[242 P, 241A], any amount of study drug - ORUG [2131:), 226A], and interven- 
tion with study drag per protocol - I [170P, 179A]) is presented below. 
P A p value RR 
ITT 17 4% I1 6% 0057 33% 
DRUG 183% 11 5=° 0 031 38% 
I 20 6"* 12 3% 0G22 41'% 
Conclusron: By preventing plateiet aggregation at the site of ba,oon 
inflation, abeiximab reduces the need for bail-out stenting dunng primary 
angioplasly for acute myocardial infarction. The effect was most pronounced 
in the group who received abciximab for ;he entire 12-hour period. Cost 
implications and polential for combined abctmmab and pnmary stenting need 
further exploration. 
t 1088-102 ] Abc ix imab Decreases  the Incidence and 
Magnitude o f  Non-Q Wave Myocardia l  In famt ion  
Assoc iated With Rotat ional  A themctomy 
G.A. Breden, WM. Love, R.J. Applegate, T.M. Young, D.C. Sane. Bowman 
Gray School of MedtcTne. Winston-Salem. NC, USA 
Creatine kinase (CK) nse/non-Q wave MI (NQMI) is common following m- 
tational atherectomy (RA) and m~y be assooated w~th long term adverse 
outcomes. Abeiximab (ReoPm) decreases the incidence of NOM! following 
PTCA and OCA, however, the benefits of ReoPro during RA have not been 
previously assessed. Acoordingly, we examined the effects of ReoPro on 
acute outcome during RA. 176 pts. received ReoPm (bolus + 12 hr infusion) 
and 150 pts. recelved tieparin (Hep) only between 10195 and 12/96, ReoPre 
pts. had lower ACT's (340 ± 6) vs. heparin (431 ± 8), p < 0,05, W~ile ReoPro 
treated pts. had more angiographically complex anatomy (AHA/ACC B2/C 
lesions 47.6% ReoPro vs. 22.9% non-ReoPre, p < 0,001). Vascular access 
complications were similar however more non-ReoPro pts. received trans- 
fusions (15.3% vs. 6.4%, p < 0.02). Thrombecytopesia (pH <100,000) was 
similar between the two groups (2.6 vs. 2.3%). CK rise following PTCRA: 
peak CK CK A 1-3, N1 ;3~N1 Any AbNI 
ReoPro 149 • 13 86 ~- 13 14% 3% 17% 
Non-ReoPro 354 +_ 100 278 = 9B 18% 12°o 30% 
P ~0.05 . 005 0.06 - 0.05 -005 
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Conclusions: Despite treating pf9, with more complex anatomy. RooPro 
use is a990clated with a 69% reduction In CK rise. ?..2% lower Incidence of 
mild CK nso and a reduction of large non.Q wave Ml's by 75%, 
1088-103 ] Abclxlmeb Inhibits Formetlon ot Platelet-derlved 
MlcmparUclea Despite Pletalat Activation 
M,G, Treuth. S, Simon. T. Chow. C.W, Smith, N.S. Klelman, BnylorCollogo 
of Mettle/rio, Hou.~ton. TX, USA 
Pl~telotoderlved micropnrllolos (PMP), pl~telat (P) membrane vesicles with 
pro¢oogul~nt prope~lles, form after P activation, Abqlxlmsb (7E3). ~ mon- 
o01on~l ~ntlbody against GP IIb.lll~. Inhibits P aggrog~tlon ~nd reduee~ 
complications of PTGA, Using whole blood flow cytomeffy, we studied ft~e 
formation el PMP In psflents meelvtng 7E3 during PTCA, Blood collected 
before and one hr after A wa~ eflm|~hllod with ADP or a strong agonlsf, 
thrombln receptor ~¢tlv~flng peptlde (TRAP), 7E3 bound 93% of at:riveted 
IIb.tll~ receptors before and 7~=81% alter stimulation, P.solccfln. an Indtca. 
for of P a~tlvetton, increased 8,7 and 10.3 fold with AOP (p ,  0,01), and 164 
and 18,t fold with TRAP (p ~ 0,00t PMP (%) worn: 
BB~alin~ 5~+M ADP ~9+,M AOP 5~.M TRAP ~O++M TRAP 
P~)~I ?E3 ~41es 11~111 I~t  t,~ ~I~ ~31 1.t 
P 00~ COl 00~ el4 O0S 
PMP were inversely proportional fo unbarred lib.Ilia mcepfera (r = 039, 
p = 0,005), Thu,'~ 7E3 inhibits PMP form~fion ~ftsr we~k slimulatlen but 
l~rmCfs some PMP formation ~fter morn infanso stimulation, Limiting PMP 
m~y represent anofhor mn(:h~ntsm by which "~E3 prevents thrombosis and 
m~y h~ve Impllclations for lib/Ilia antagonisfs In Coronary syndromes whom 
thmmbln provides an Inton~o sfimulus for P activation end PMP fermafion, 
• Synargy of Abolxlmsb and Tlclopldlne In 
Patients Undergoing Intracoronary Stentlng 
N,~, Klelman, N, Grat.ladoi, E, Lance, K, Mamsh, J. Taylor, J. Higglnbotham, 
A, Edwards, M,B, Effmn, M,A, Mascelli, R,E, Jordan, BaylorCoflege of 
Me¢ltctne, Houston. T+~,qnd Centocor In[',, Mah,Pm, P~, USA 
TIclopldlne iT) and abcixlmab (abx) exhibit different pharmacadynamtc pro- 
files and both are often usod during slant placement, To study their inferaction, 
we measured Inhibition of platelet aggregation (IPA) to 5 ~M ADP and 8 ~=M 
TRAP, and GP lib-Ilia receptor blockade (RB) in patient9 receiving steels. All 
paftent9 received nspinn end T 12-18 hours prior to PTCA; half also mcoivod 
abx immediately peer. ]'ime wee moasurod from abx administrabon. IPA for 
ADP was: 
Po.~t T 2 H 24 H 3 ID 713 14 D 
T 4. obx 7 t 8 94 ~ 2 64 .t 4 49 t" 6 47 '~ 13 43 ~ 12 
T 11.16 10:16 1S~9 25±8 4S~14 21±13 
P 0,01 000008 00042 064 0,45 038 
In response fo TRAP, IPA for T + abx was less profound, peaking at 47% 
at bye hours, and falling to 13% at 3 days and 22% at 14 days, compared 
with 6%, 4%, 1% re9pecfively for T only. RB at 2 hrs was 90% for T + abx and 
declined to baseline 81 14 days. T alone led to minimal change in RB. Thus, 
the combination of T and abx allowed profound inltnl IPA compared with 
T alone; pit aggregation Mmained inhibited even when receptor availability 
Mtumod to beeolino. Abx hod little effect on the late action of 3. Theso 
findings provide mechanistic support for the simultaneous use of T and abx 
1 088-105 ] Incidence of Bleeding Complications Associated 
With Abclxlmab Huse In Con[unction With 
Thrombolytlo Therapy In Patients Requiring 
Angioplasty 
D.W Sundlof, P. Reprkpatfanspitet, N Wongpraparut, P. Pathi. M.N, Keller. 
LE. Jacobs, S. Yazdanfar Albert Einstein Medical Center. Philadelphia. PA. 
USA 
Background: With the more widespread use of Abciximab (Abx) as an adjunct 
to angiopla9ty (PTCA) during acute myocardial infarction (MI). the safety of 
the combination therapy of thrombolytics and abx should be more clearly 
defined. 
Methods: A retrospective analysis was performed in 100 acu', " ~! p~.t!c."*.s 
who unde=~vent PTCA with adjunctive Abx therapy. Patients were divided ;eta 
three groups: A (Rescue PTCA within 15 hr of thrombolytics) n = 22, B (suc- 
cessful thrombolytictherapy followed by elective PTCA) n = 34. and C (primary 
PTCA) n = 44. All patient8 received Abx 89 a 0.25 mg/kg bolus followed by an 
Infusion of 101~g/rain for 12 hours. Bleedin9 was classified 88 major, miner, or 
insignificant according to the criteria of the TIMI Study Group. 
Results: 
Group A Group B Group C 
tnsigniflcnnt Bleed 14 (64%) 31 (91%) 33 (75%) 
Minor ble~,d 4 (18%) 3 (9%) 10 (~3%) 
Meier bleed 4 (18%) 0 t (2%) 
Major bleeding occurred ream frequently In group A versus group B (p 
~: 0,02) end group C (p .~ 0,04), Two intragraninl hemormagos occurred in 
group A only. 
Conclusion: There is n significant incre~se ,n m~lor b t~ ing  complications 
whoa Aboixim~b Is used In conlunolien with 'rescue ¢ngiop!~sty" within 15 
hr after f~iled Ihrombolyti¢ therapy, 
~ "Bailout n e?E30ur lng Comna~/ Intervent ion:  
Aq=ute Results end Long-term !+OllOw,up 
D,E, Rshmsnn, JA+ Krupp, B+ Go!d0erg, M,P, Savage+ Jefferson Me~/i~l 
Collage. Phit~cletphla, ~nns.t,tvam~. US4 
Prier studios have 6hawr the efficacy of C?E3 in decreasing ischemie compli, 
Cations when given immediately pear 1o ." TCA The purpose of this study was 
to avail.late the efficacy of "bailout" c7E3 on acute and Iong.tem~ oulcoale 
after coronary intervention, 95 patients undenNent corona~ intervention w~th 
~diunctiv8 7E3; 58 patients treated pmphylact~e!ly, and 3? patients fwated 
provist0nally for s~baptimal response to initial intervention (bailout), Proce- 
dural Su~-'ess was achieved in all 37 bailout patients (10(]%). There weM 
no tn.ho9pifal desfhs, Q.MI, CABG or repast PTCA: ~ patmnts e~tpefleeced 
non Q.MI (5.4%), Comparison of the prophylactic and bailout c7E3 patients 
demonstrated no significant difference in in.hospital cardiP.~- compbcations 
(3,4 va 5,4%) or vascular complications (10.3 vs 5,4%). Late clin¢..al fol- 
low-up at ~_1 year (range 13--28 months) was obtained in all 37 bailout 
patients (see table), 
Death CABG MI RePTCA Any Event 
30 day 0 0 2 (54%) O ;~ t54%) 
: 1 yeast 1 t~ 7%) 2 (54%t 2 t54%) tO (~7~ot 15 (40.5%) 
Following hospital discharge, them were no cardiac events in bailout 
patients within 30 days. However. late follow-up revealed cardiac events 
in 15 (40,5%) pabents predominantly due to clinical mstenosis and repeat 
Mvascutanzation, 
Conclusions: Use of c7E3 in a bailout fashion is associated w=th igh 
procedural success, m-hospital outcomes comparable to prophylactic use, 
and a low 30 day cardiac event rate. However, the potential tar late restenosts 
is not eliminated. Further prospective foals of this strategy aM needed 
1~8~ Initial Report of Gamma Radiotherapy for  Diffuse 
" Coronary Restenosla: The SCRIPPSll Trials 
Paul S Teirsteln, Vincent Massullo, Shirish Jani, Jeffrey J. Popma, Robert 
J, Ruses, Stephen Steutennan. Shela Norman, Martin B. Leon. 
Prbkahar Tnp~-anemL Scripps Clinic. La Jells. CahfoMia. USA 
Gamma radiatit.n has been shown to reduce coronary restenosis in patients 
with discrete (d30 ram) lesion lengths. In a subsequent rial (the SCRIPPS II 
Trial), we randomized 51 patients with diffuse restenotic segments up to 65 
mm in lesion length A blind lumen radiation delivery catheter was used to 
lesion, 
It- 192 Placebo 
n=26 n=25 
Lesion length (mm) 1607 ± 12.43 13.91 ± 7.48 NS 
Length. 10 mm 56% 60"0 NS 
Vessel diameter ( am) 249 ± 045 2.56 • 0.50 NS 
MLD Pre (mm) 0 70 ± 0.45 0.61 ± 0.37 NS 
MLO Post (ram) 2.74 ± 0.45 295 ± 053 NS 
DoathlMI/CABG O/O/O Ot0tO 
In 2 patients, the study catheter partially obstructed flow resulting in 
significant ischemia requiring interruption of treatment. In both cases the 
source wire was withdrawn in < 20 seconds. 
Conclusion: Coronary ischemia may occur dudng gamma irradiation of 
diffuse, small vessel di.~a.qe, but catheters can be quickly withdrawn with- 
out jeopardizing patient safety. Interim analysis of 6-month outcome will be 
presented. 
